LUMOSA THERAPEUTICS Business Summary

Lumosa Therapeutics Ltd (6535.TWO) operates under a specialized "reSEARCH and DEVELOPMENT" business model, focusing on scientific licensing and the clinical development of first-in-class and best-in-class new drugs. The company generates revenue through a combination of upfront licensing fees, milestone payments from global partnerships, and product sales of its approved long-acting analgesic, Naldebain (LT1001). Its primary business segments are Neuroscience, led by its flagship stroke candidate LT3001, and Oncology, which targets solid tumors. Within the competitive landscape, Lumosa contends with clinical-stage biotechs such as Flexion Therapeutics, Cara Therapeutics, and Eliem Therapeutics; it distinguishes itself by targeting the high-unmet-need "golden hour" and beyond for acute ischemic stroke with a dual-functional thrombolytic and neuroprotective mechanism. The company is led by Chairperson Su-Chi Wang, who also holds a senior leadership role at Center Laboratories, and General Manager Sheng-Wen Yeh (Mimi), Ph.D., a specialist in preclinical translation and molecular biology with a doctorate from the University of Bath. The executive team is supported by Chief Financial Officer Chia Chi Yang and June Kuo, who oversees clinical development and R&D strategy. Lumosa was originally founded in 2000 as SunTen Phytotech before undergoing a series of strategic mergers in 2014 to consolidate its current pipeline. The company maintains a strong institutional pedigree, with Center Laboratories, Inc. serving as its largest shareholder and strategic partner, providing significant financial and industrial backing for its global Phase 2 and Phase 3 clinical programs.